Training and Fidelity Monitoring of Alcohol Treatment Interventions Integrated Into Routine Tuberculosis Care in Tomsk, Russia: the IMPACT Effectiveness Trial

IMPACT (Integrated Management of Physician-Delivered Alcohol Care for Tuberculosis patients) is a randomized, controlled effectiveness trial based in Tomsk, Russia, that assesses the effect of oral naltrexone and brief behavioral counseling on tuberculosis outcomes and alcohol use in 200 patients. T...

Full description

Saved in:
Bibliographic Details
Published in:Substance use & misuse 2013-06, Vol.48 (9), p.784-792
Main Authors: Connery, Hilary, Greenfield, Shelly, Livchits, Viktoriya, McGrady, Lana, Patrick, Nickolette, Lastimoso, Charmaine S., Heney, Jessica H., Nelson, Adrianne Katrina, Shields, Alan, Stepanova, Yekaterina P., Petrova, Lidia Y., Anastasov, Oleg V., Novoseltseva, Olga I., Shin, Sonya S.
Format: Article
Language:English
Subjects:
Addictive behaviors
Alcohol Abuse
alcohol interventions
Alcohol related
Alcohol use
alcohol use disorders
Alcoholism - complications
Alcoholism - drug therapy
behavioral interventions
cross-cultural clinical trials
Doctors
Effectiveness studies
effectiveness trials
Fidelity
fidelity monitoring
Guideline Adherence
Intervention
Interventions
Medical Research
Naltrexone - therapeutic use
Narcotic Antagonists - therapeutic use
Patients
Physicians
Russia
Substance abuse treatment
Training
Treatment Outcomes
Trials
Tuberculosis
Tuberculosis - complications
Tuberculosis - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IMPACT (Integrated Management of Physician-Delivered Alcohol Care for Tuberculosis patients) is a randomized, controlled effectiveness trial based in Tomsk, Russia, that assesses the effect of oral naltrexone and brief behavioral counseling on tuberculosis outcomes and alcohol use in 200 patients. Tuberculosis physicians without addiction experience delivered interventions as part of routine care over a 6-month period, focusing on alcohol intake reduction to support successful tuberculosis treatment. We describe design, training, and fidelity monitoring using a Russian and American team of physicians, bilingual coders, and supervisors. Culturally appropriate adaptations, limitations, and implications for future trials are discussed. The clinical trial identification number is NCT00675961. Funding came from the National Institutes of Health and National Institute on Drug Abuse.
ISSN:1082-6084
1532-2491
DOI:10.3109/10826084.2013.793715